https://www.globenewswire.com/news-release/2021/05/20/2232978/0/en/ObsEva-Announces-Final-Results-from-the-Phase-3-PRIMROSE-Program-of-Yselty-linzagolix-for-the-Treatment-of-Uterine-Fibroids.html
ObsEva Announces Final Results from the Phase 3 PRIMROSE
-PRIMROSE 1 76-week results confirm PRIMROSE 2 data showing sustained post-treatment effects and evidence of bone mineral density (BMD) recovery following...
final resultsfrom theannouncesphaseprimrose